2021 Volume 33 Issue 4 Pages 290-298
［Objectives］ To assess the effectiveness and safety of Igratimod（IGU）in rheumatoid arthritis（RA）.
［Methods］ Two hundred eighty-eight RA patients had been treated with IGU in our hospital from October 2012 to January 2018, and 261 of them continued IGU for more than three months. We divided them into some groups; under 75 years old and 75 years old or higher, those treated with methotrexate（MTX）and without MTX, and those treated with biologics（BIO）and without BIO. We investigated the retention rate, adverse events（AEs）and clinical response over 2 years.
［Results］ The mean DAS28-ESR/SDAI at 2 years was 2.7/5.9, which significantly decreased from the baseline. The EULAR moderate response rates by under or over 75 years old at 2 years were 66.2% and 68.3%, and ACR20 response rates were 46.0% and 42.4%, respectively. The EULAR moderate response rates by with or without MTX at 2 years were 68.1% and 64.2%, and ACR20 response rates were 46.6% and 42.5%, respectively. Similarly, the EULAR moderate response rates by with or without biologics at 2 years were 57.0% and 69.9%, and ACR20 response rates were 37.0% and 48.0%, respectively. The incidence rate of AEs was 18.5% among the 288 patients and the skin eruption was the most frequent. The retention rate at 2 years was 81.1%.
［Conclusion］ These data indicate IGU therapy is effective and safe regardless of age, and the use of MTX and BIO.
